Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is a novel oral NLRP3 inflammasome inhibitor
The company is focused on the development of novel treatments for RNA viruses
Subscribe To Our Newsletter & Stay Updated
